1-2 of 2
Russell Moser
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Shogo Shigeta, Goldie Y.L. Lui, Reid Shaw, Russell Moser, Kay E. Gurley, Grace Durenberger, Rachele Rosati, Robert L. Diaz, Tan A. Ince, Elizabeth M. Swisher, Carla Grandori, Christopher J. Kemp
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (4): 691–703.
https://doi.org/10.1158/1535-7163.MCT-20-0809
Published: 01 April 2021
View article titled, Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Open the PDF for Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract PR05: Construction of synthetic lethal networks for p53 tumor suppressor pathways identifies candidate therapeutic targets for metastatic, chemotherapy resistant HNSCC

Russell Moser, Chang Xu, Michael Kao, In Sock Jang, Kay Gurley, Adam Margolin, Carla Grandori, Eddie Mendez, Chris Kemp
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): PR05.
https://doi.org/10.1158/1535-7163.PMS-PR05
Published: 01 May 2014
View article titled, Abstract PR05: Construction of synthetic lethal networks for p53 tumor suppressor pathways identifies candidate therapeutic targets for metastatic, chemotherapy resistant HNSCC